Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-23T00:35:32.586Z Has data issue: false hasContentIssue false
  • English
  • Français

The fourth edition of the European Network for Health Technology Assessment Forum: highlights and outcomes

Published online by Cambridge University Press:  22 April 2020

Giovanni Tafuri Open the ORCID record for Giovanni Tafuri [Opens in a new window] ,
Chantal Bélorgey ,
Carlo Favaretti ,
Edith Frénoy ,
Flora Giorgio ,
Marcus Guardian ,
Ansgar Hebborn ,
François Houÿez ,
Jessica Imbert  and
Denis Lacombe
...Show all authors
Giovanni Tafuri*
Affiliation:
Zorginstituut Nederland (ZIN), Willem Dudokhof 1, 1112ZADiemen, The Netherlands
Chantal Bélorgey
Affiliation:
Haute Autorité de Santé (HAS), 5 Avenue du Stade de France, 93210Saint-Denis, France
Carlo Favaretti
Affiliation:
European Public Health Association (EUPHA), Otterstraat 118, 3513CRUtrecht, The Netherlands Centre on Leadership in Medicine, Catholic University of the Sacred Heart, Largo F. Vito 1, 00168Rome, Italy
Edith Frénoy
Affiliation:
European Federation of Pharmaceutical Industries and Associations (EFPIA), Rue du Trône, 1050Ixelles, Belgium
Flora Giorgio
Affiliation:
European Commission, Directorate General for Health and Food Safety, Rue Breydel 4, 1000Brussels, Belgium
Marcus Guardian
Affiliation:
Zorginstituut Nederland (ZIN), Willem Dudokhof 1, 1112ZADiemen, The Netherlands
Ansgar Hebborn
Affiliation:
F. Hoffmann-La Roche AG, Pharmaceutical Division, Basel, Switzerland
François Houÿez
Affiliation:
European Organisation for Rare Diseases (Eurordis), 96 rue Didot, 75014Paris, France
Jessica Imbert
Affiliation:
MedTech Europe, Rue Joseph II 40, 1000Brussels, Belgium
Denis Lacombe
Affiliation:
European Organisation for Research and Treatment of Cancer (EORTC), Avenue E. Mounier 83, 1200Brussels, Belgium
Jordi Llinares Garcia
Affiliation:
European Medicines Agency (EMA), Domenico Scarlattilaan 6, 1083HNAmsterdam, The Netherlands
Zoe Garrett
Affiliation:
National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Elena Petelos
Affiliation:
European Public Health Association (EUPHA), Otterstraat 118, 3513CRUtrecht, The Netherlands European Forum for Primary Care (EFPC), Otterstraat 118, 3513CRUtrecht, The Netherlands Clinic of Social and Family Medicine, Faculty of Medicine, University of Crete, Voutes University Campus, 70013HeraklionCrete, Greece Health Services Research Department, Care and Public Health Research Institute (CAPHRI), Faculty of Health, Medicine and Life Sciences, Maastricht University, Minderbroedersberg 4-6, 6211 LKMaastricht, The Netherlands
Ingvil Saeterdal
Affiliation:
Norwegian Institute of Public Health (NIPH), PO Box 222 Skøyen, 0213Oslo, Norway
Ad Schuurman
Affiliation:
Zorginstituut Nederland (ZIN), Willem Dudokhof 1, 1112ZADiemen, The Netherlands
Anna Lefevre Skjöldebrand
Affiliation:
Swedish Medtech, Sveavägen 63, 113 59Stockholm, Sweden
Valentina Strammiello
Affiliation:
European Patients' Forum (EPF), Chaussée d'Etterbeek 180, 1040Etterbeek, Belgium
Daniel Widmer
Affiliation:
European Union of General Practitioners (UEMO), Rue des Deux Églises 37-39, 1000Brussels, Belgium
Anne Willemsen
Affiliation:
Zorginstituut Nederland (ZIN), Willem Dudokhof 1, 1112ZADiemen, The Netherlands
Niklas Hedberg
Affiliation:
Tandvårds & Läkemedelsförmånsverket (TLV), Fleminggatan 18, 112 26Stockholm, Sweden
*
Author for correspondence: Giovanni Tafuri, E-mail: [email protected]; [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

The European Network for Health Technology Assessment (EUnetHTA) organizes an annual Forum with stakeholders to receive feedback on its activities, processes, and outputs produced. The fourth edition of the EUnetHTA Forum brought together representatives of HTA bodies, patient organizations, healthcare professionals (HCPs), academia, payers, regulators, and industry. The aim of this paper is to provide an overview of the highlights presented at the 2019 EUnetHTA Forum, reporting the main items and themes discussed in the plenary panel and breakout sessions. The leading topic was the concept of unmet medical need seen from different stakeholders' perspectives. Breakout sessions covered the joint production of assessment reports and engagement with payers, patients, and HCPs. Synergies, pragmatism, and inclusiveness across Member States and stakeholders were emphasized as leading factors to put in place a collaboration that serves the interest of patients and public health in a truly European spirit.

Keywords

EUnetHTAForumEuropean CommissionHTA
Type
Article Commentary
Information
International Journal of Technology Assessment in Health Care , Volume 36 , Issue 3 , June 2020 , pp. 191 - 196
Copyright
Copyright © Cambridge University Press 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

EURODIS. Breaking the Access Deadlock to Leave No One Behind. A contribution by EURORDIS and its Members on possibilities for patients' full and equitable access to rare disease therapies in Europe. 2018. Available from: http://download2.eurordis.org.s3.amazonaws.com/positionpapers/eurordis_access_position_paper_final_4122017.pdf.Google Scholar
Proposal for a Regulation of the European Parliament and of the Council on health technology assessment and amending Directive 2011/24/EU [cited 2019 Dec 3]. Available from: https://ec.europa.eu/health/sites/health/files/technology_assessment/docs/com2018_51final_en.pdf.Google Scholar
European Medicines Agency. PRIME: priority medicines [cited 2019 Dec 3]. Available from: https://www.ema.europa.eu/en/human-regulatory/research-development/prime-priority-medicines.Google Scholar
Ministère des Solidarités et de la Santé. Le forfait innovation [cited 2019 Dec 3]. Available from: https://solidarites-sante.gouv.fr/systeme-de-sante-et-medico-social/recherche-et-innovation/forfait-innovation.Google Scholar
United Nations. Sustainable development goals [cited 2020 Jan 28]. Available from: https://sustainabledevelopment.un.org/sdg3.Google Scholar
World Health Organization. Ensure healthy lives and promote wellbeing for all at all ages (Sub-goal of 3.8 of SDG3) [cited 2019 Dec 3]. Available from: https://www.who.int/sdg/targets/en/.Google Scholar
European Network for Health Technology Assessment. Topic Identification, Selection and Prioritisation (TISP) [cited 2019 Dec 3]. Available from: https://eunethta.eu/services/horizon-scanning/.Google Scholar
European Network for Health Technology Assessment. EUnetHTA Procedure Guidance for handling the Declaration of Interest [cited 2019 Dec 3]. Available from: https://eunethta.eu/doi/.Google Scholar
European Network for Health Technology Assessment. Patient Input in Relative Effectiveness Assessments [cited 2019 Dec 3]. Available from: https://eunethta.eu/wp-content/uploads/2019/06/Final_290519_Patient-Input-in-REAs.pdf.Google Scholar
Pontes, C, Zara, C, Torrent-Farnell, J, Obach, M, Nadal, C, Vella-Bonanno, P, et al. Time to review authorisation and funding for new cancer medicines in Europe? Inferences from the case of Olaratumab. Appl Health Econ Health Policy. 2020;18:5–16.CrossRefGoogle ScholarPubMed
Ermisch, M, Bucsics, A, Vella Bonanno, P, Arickx, F, Bybau A payers’ views of the changes arising through the possible adoption of adaptive pathways. Front Pharmacol. 2016;7:305.CrossRefGoogle Scholar
Vella Bonanno, P, Ermisch, M, Godman, B, Martin, AP, Van Den Bergh, J, Bezmelnitsyna, L, et al. Adaptive pathways: Possible next steps for payers in preparation for their potential implementation. Front Pharmacol. 2017;8:497.CrossRefGoogle Scholar
European Medicines Agency. EMA-EUnetHTA three-year work plan [cited 2019 Dec 3]. Available from: https://www.ema.europa.eu/en/documents/other/ema-eunethta-three-year-work-plan-2017-2020_en.pdf.Google Scholar
Vreman, RA, Heikkinen, I, Schuurman, A, Sapede, C, Garcia, JL, Hedberg, N, et al. Unmet medical need: an introduction to definitions and stakeholder perceptions. Value Health. 2019;22:1275–128.CrossRefGoogle ScholarPubMed
Supplementary material: PDF

Tafuri et al. supplementary material

Tafuri et al. supplementary material

Download Tafuri et al. supplementary material(PDF)
PDF 190.7 KB